DENTSPLY SIRONA Inc. $XRAY Shares Purchased by Private Management Group Inc.

Private Management Group Inc. increased its stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 47.4% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,470,726 shares of the medical instruments supplier’s stock after acquiring an additional 794,107 shares during the quarter. Private Management Group Inc.’s holdings in DENTSPLY SIRONA were worth $26,214,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in DENTSPLY SIRONA during the second quarter valued at $283,405,000. Southpoint Capital Advisors LP acquired a new stake in shares of DENTSPLY SIRONA in the first quarter valued at about $116,000,000. AQR Capital Management LLC increased its stake in shares of DENTSPLY SIRONA by 109.8% during the second quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock worth $211,470,000 after purchasing an additional 6,970,086 shares in the last quarter. Armistice Capital LLC raised its position in shares of DENTSPLY SIRONA by 1,044.0% during the 3rd quarter. Armistice Capital LLC now owns 5,736,000 shares of the medical instruments supplier’s stock worth $72,790,000 after purchasing an additional 5,234,587 shares during the last quarter. Finally, Edmond DE Rothschild Holding S.A. acquired a new position in shares of DENTSPLY SIRONA during the 2nd quarter worth about $47,780,000. 95.70% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Brian T. Gladden bought 9,985 shares of the firm’s stock in a transaction on Monday, June 15th. The shares were bought at an average cost of $10.02 per share, for a total transaction of $100,049.70. Following the acquisition, the director directly owned 61,849 shares of the company’s stock, valued at $619,726.98. This trade represents a 19.25% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Michael J. Barber purchased 15,175 shares of DENTSPLY SIRONA stock in a transaction dated Thursday, June 11th. The shares were purchased at an average cost of $9.88 per share, for a total transaction of $149,929.00. Following the transaction, the director owned 55,943 shares in the company, valued at approximately $552,716.84. This trade represents a 37.22% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders bought 35,160 shares of company stock worth $351,179. Insiders own 0.46% of the company’s stock.

Trending Headlines about DENTSPLY SIRONA

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Zacks Research increased its FY2026 EPS estimate to $1.50 from $1.41, above the current consensus estimate of $1.41. This is the clearest supportive factor for DENTSPLY SIRONA (XRAY) today.
• Neutral Sentiment: Zacks maintained estimates of $1.50 EPS for FY2027 and $1.64 EPS for FY2028 in its updated forecast set, providing some stability despite reductions to individual periods.
• Negative Sentiment: The firm lowered its Q3 2026 EPS estimate to $0.31 from $0.37 and cut Q4 2026 EPS to $0.40 from $0.41. The Q3 revision is particularly notable because it represents a larger reduction in expected near-term profitability.
• Negative Sentiment: Additional cuts included Q2 2027 EPS to $0.38 from $0.39, Q3 2027 EPS to $0.41 from $0.42, Q4 2027 EPS to $0.39 from $0.40, Q1 2028 EPS to $0.35 from $0.37, Q2 2028 EPS to $0.41 from $0.42, and FY2028 EPS to $1.64 from $1.65.

Wall Street Analyst Weigh In

XRAY has been the topic of several research analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of DENTSPLY SIRONA in a report on Monday, August 3rd. UBS Group reduced their target price on DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Barclays raised their target price on DENTSPLY SIRONA from $9.00 to $11.00 and gave the company an “underweight” rating in a research report on Monday, August 24th. BMO Capital Markets reaffirmed a “market perform” rating and issued a $13.00 price target on shares of DENTSPLY SIRONA in a research note on Friday, August 7th. Finally, Piper Sandler boosted their price target on DENTSPLY SIRONA from $13.00 to $14.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 29th. Three investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $13.54.

DENTSPLY SIRONA Trading Up 0.7%

Shares of DENTSPLY SIRONA stock opened at $11.12 on Friday. The stock has a market cap of $2.22 billion, a P/E ratio of -4.04, a P/E/G ratio of 1.39 and a beta of 0.85. The stock’s 50 day simple moving average is $12.10 and its 200-day simple moving average is $11.75. DENTSPLY SIRONA Inc. has a 1-year low of $9.40 and a 1-year high of $14.86. The company has a debt-to-equity ratio of 1.48, a current ratio of 1.63 and a quick ratio of 1.07.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 EPS for the quarter, beating the consensus estimate of $0.35 by $0.17. The firm had revenue of $898.00 million during the quarter, compared to analysts’ expectations of $889.93 million. DENTSPLY SIRONA had a positive return on equity of 20.84% and a negative net margin of 14.99%.The business’s revenue for the quarter was down 4.1% on a year-over-year basis. During the same quarter last year, the firm earned $0.52 earnings per share. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Analysts predict that DENTSPLY SIRONA Inc. will post 1.4 EPS for the current fiscal year.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.